Ahmad Shoeb Hashmi

Dr. Ahmad Shoeb Hashmi

Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2026 in International Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
Ahmad Shoeb HashmiAhmad Shoeb Hashmi
Ahmad Shoeb Hashmi
NGN.D. Gupta
N.D. Gupta
SKSAIF KHAN
SAIF KHAN
SAS.A. Ali
S.A. Ali
OKO. Kulsum
O. Kulsum
Valentino VelloneValentino Vellone
Valentino Vellone

31 March 2026 in Applied Sciences
Verified
Journal Article
Open access
PDF file
Valentino VelloneValentino Vellone
Valentino Vellone
Giulia RomanelliGiulia Romanelli
Giulia Romanelli
Ahmad Shoeb HashmiAhmad Shoeb Hashmi
Ahmad Shoeb Hashmi
DADaniela Adamo
Daniela Adamo
PSPedro Sampaio
Pedro Sampaio
VVValentino Valentini
Valentino Valentini
Alveolar osteitis (AO) and postoperative pain are common complications after dental extractions. Excessive fibrinolysis leading to premature clot loss contributes to AO. Tranexamic acid (TXA), an antifibrinolytic agent, may stabilize post-extraction blood clots and reduce AO, although evidence from randomized controlled trials (RCTs) remains inconsistent. This systematic review and meta-analysis evaluated the effectiveness of topical TXA in preventing AO and reducing postoperative pain following dental extractions. PubMed, Embase, Scopus, and CENTRAL were searched from inception to June 2025 using terms related to “dental extraction” and “tranexamic acid”. Only English-language human studies were included. Eligible studies were RCTs assessing topical TXA versus placebo, saline, or plain gauze, reporting AO and/or pain outcomes. Non-RCTs, in vitro or animal studies, and trials lacking relevant outcomes or controls were excluded. Two reviewers independently screened and selected studies. Following PRISMA guidelines, two reviewers extracted data and assessed risk of bias with the Cochrane RoB-2 tool. Pooled analyses used random-effects models, with risk ratios (RRs) for AO and standardized mean differences (SMDs) for pain. AO was defined as exposed bone, foul odor, or persistent pain after day 3. Pain was measured on the Visual Analogue Scale (VAS) on days 3 and 7. Five RCTs (378 patients) were included. TXA significantly reduced AO incidence compared with controls (RR = 0.49; 95% CI: 0.32–0.76; p = 0.001; I2 = 0%), indicating a ~50% risk reduction. Pain outcomes showed no significant differences on day 3 (SMD = −0.36; 95% CI: −0.95 to 0.24; p = 0.24; I2 = 84%) or day 7 (SMD = −0.43; 95% CI: −1.34 to 0.48; p = 0.36; I2 = 93%). Topical TXA significantly reduces the risk of AO after dental extraction, while its effect on postoperative pain remains inconsistent. Its safety, accessibility, and low cost support its use as a preventive adjunct in dental extractions. Further standardized, high-quality RCTs are needed to clarify its role in pain management.

1 October 2026 in Diseases
Verified
Journal Article
Open access
PDF file
Darya Khalid MahmoodDarya Khalid Mahmood
Darya Khalid Mahmood
AHArivan Mahmood Hama
Arivan Mahmood Hama
Ahmad Shoeb HashmiAhmad Shoeb Hashmi
Ahmad Shoeb Hashmi
Background/Objectives: Understanding the biological role of the receptor activator of nuclear factor-κB ligand (RANK), its ligand (RANKL), and the decoy receptor osteoprotegerin (OPG) is vital for clarifying the pathogenesis of gnathic giant cell-containing lesions and directing targeted clinical treatments. Methods: Following PRISMA 2020 guidelines and a registered PROSPERO protocol [CRD420261461026], we searched PubMed, Scopus, and Web of Science databases for human tissue-level or clinical denosumab studies (2003–2026). Quality was appraised using adapted NOS and JBI checklists. A fixed-effect inverse-variance meta-analysis pooled continuous RANK parameters between aggressive and non-aggressive CGCG subtypes. Results: Eleven primary tissue-marker studies (259 specimens; two previously considered studies were excluded as unpublished, non peer-reviewed sources) and 10 non-overlapping clinical cohorts/case reports (58 patients total: 55 from 7 multi-patient cohorts + 3 single-case reports [Hameed, O’Connell, Kawamura]). Mononuclear stromal cells represent the pathogenetic driver, secreting RANKL to recruit RANK-expressing mature giant cells. Meta-analysis (k = 2 studies) showed that raw membrane RANK-positive cell percentages did not differ significantly between aggressive and non-aggressive phenotypes (pooled Hedges’ g = 0.25, 95% CI −0.29–0.80, p = 0.36), while non-aggressive lesions showed a borderline, non-significant trend toward higher staining intensity-distribution (SID) scores (g = 0.55, 95% CI −0.00–1.11, p = 0.0506). Because this 95% CI crosses zero, and only two studies (k = 2) were pooled, this represents a non-significant trend rather than a statistically confirmed difference between aggressive and non-aggressive CGCG; both pooled estimates are, therefore, hypothesis-generating only. In clinical cohorts, denosumab achieved objective clinical and radiological tumor responses in all reported cases, enabling downstaging from disfiguring resection to conservative curettage. However, post-cessation recurrence was frequent, ranging from 37% in adults to 100% in pediatric cohorts, with pediatric patients at risk of rebound hypercalcemia. Conclusions: The RANK/RANKL/OPG axis, driven by RANKL-secreting mononuclear stromal cells, underlies osteolytic activity in gnathic giant cell lesions. Denosumab is an effective neoadjuvant bridge to jaw-preserving surgery but is not curative; a RANKL-independent, OPG-resistant SOFAT pathway has been hypothesized as one possible contributor to treatment failure, although this proposal is derived from a single external study and requires independent validation before any clinical inference is drawn. Close post-treatment metabolic and radiographic surveillance is warranted in pediatric patients. Prospective studies are needed to define optimal weaning protocols.


14 September 2026 in International Journal of Dental Hygiene
Verified
Journal Article
Closed access
OKOnaiza Kulsum
Onaiza Kulsum
PSPedro Sampaio
Pedro Sampaio
Ahmad Shoeb HashmiAhmad Shoeb Hashmi
Ahmad Shoeb Hashmi
NGNarinder Dev Gupta
Narinder Dev Gupta
SKSAIF KHAN
SAIF KHAN